Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.

People who lost significant weight while taking Ozempic, Wegovy, Mounjaro, or Saxenda had sharply lower risks of major ...

Obesity has become one of the biggest health challenges in the world. Millions of people struggle with excess weight, and ...

Rising Oncology Cases, Patent Expirations of Blockbuster Biologics, and Strategic Collaborations Among Leading Biopharma ...

New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following ...

Research shows sick leave among patients prescribed GLP-1 injections over nine-month period reduced by 50% ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that ...

New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important ...

On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...

In recent years, weight-loss drugs have become a common addition to diet and exercise routines. The rise of GLP-1 medications ...

Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage. A nutrient-dense diet and regular exercise a ...